)
Edge20 Mar 2026
Tetra Pak: The Shape of Innovation
The story of Tetra Pak, the Rausing family, and how a paper tetrahedron gave rise to a company that now delivers almost 180 billion packages a year.
Matinas BioPharma
Matinas BioPharma (MTNB) investor relations material
Matinas BioPharma Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary31 Mar, 2026
Executive summary
Clinical-stage biopharma focused on lipid nanocrystal (LNC) platform, with lead candidate MAT2203 (oral amphotericin B) for invasive fungal infections, currently paused pending partnership or capital raise.
80% workforce reduction in late 2024, cost-cutting measures, and halted internal pipeline development to conserve cash.
Ongoing efforts to secure a partner or sale for MAT2203; failure may result in company winddown or dissolution.
Financial highlights
Net loss for 2025 was $10.3 million, down from $24.3 million in 2024.
No revenue generated in 2025 or 2024; accumulated deficit reached $210.8 million as of December 31, 2025.
Cash and cash equivalents at year-end 2025 were $4.0 million, not sufficient to fund operations beyond the next 12 months.
Research and development expenses dropped sharply to $85,000 in 2025 from $11.4 million in 2024 due to program pause and workforce reduction.
General and administrative expenses were $6.9 million in 2025, down from $8.7 million in 2024.
No impairment charges in 2025; $4.4 million in impairment charges recorded in 2024 related to goodwill, IPR&D, and other assets.
Outlook and guidance
Substantial doubt exists about ability to continue as a going concern without additional capital or a partnership.
Expenses expected to remain low until additional funding or a partnership is secured; resumption of MAT2203 development would increase costs.
No expectation of product revenue for several years, if ever.
Mitigation of Rutgers license termination risk
Series A royalty impact on licensing proceeds
Partner flexibility to revise ORALTO trial
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Matinas BioPharma
- Oral MAT2203 could transform antifungal therapy by offering safer, more flexible treatment.MTNB
Fireside Chat3 Feb 2026 - MAT2203 licensing advances, net loss narrows, but cash shortfall raises going concern doubts.MTNBQ2 20241 Feb 2026
- Registering 16.9M shares for resale post-private placement, with ongoing strategic and financial risks.MTNBRegistration Filing16 Dec 2025
- Proxy seeks approval for director elections, compensation, reverse split, share increase, and new equity plan.MTNBProxy Filing2 Dec 2025
- Proxy seeks approval for director elections, compensation, reverse split, share increase, and new equity plan.MTNBProxy Filing2 Dec 2025
- Approval sought for major stock issuance, auditor ratification, and potential meeting adjournment.MTNBProxy Filing2 Dec 2025
- Vote on major stock issuance, auditor ratification, and board changes at April 2025 virtual meeting.MTNBProxy Filing2 Dec 2025
- Net loss narrowed, cash declined, and going concern risk persists pending new funding.MTNBQ3 202510 Nov 2025
- Ceased all product development and cut 80% of workforce after failed MAT2203 deal; cash at $10.8M.MTNBQ3 20248 Oct 2025
Next Matinas BioPharma earnings date
Q1 202613 May, 2026
Matinas BioPharma
Next Matinas BioPharma earnings date
Q1 202613 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage